We believe Q2 was good news for the base business given that 1) BD revenues grew strongly and were a testament that the Q1 drop was temporar...
Bactiguard’s Q2 net sales of SEK 54m came in +11% vs SEB (SEK 49m).
We believe Q2 has had a better set-up compared to prior quarters as both BD and Wound Management revenues face easier comps, which should al...
We argue that low Q1 sales are no problem. We have historically learnt that BD revenues (concentrate) may show quarterly volatility and the ...
Q1 net sales of SEK 42m came in much below SEB (SEK 49m) with organic net sales decline of 17% y/y in the quarter.
While we believe there are growth levers in the existing business, we think further license deals are needed to reignite the equity story.
Given that Q4 was broadly in line excluding one-off revenue, our estimate revisions are limited overall and our valuation range remains SEK ...
Bactiguard reported Q4 net sales of SEK 63m (SEB at SEK 49m) with organic net sales growth of 4% y/y driven by Zimmer revenue.
Our revisions are material, as we remove the US contribution from the Zimmer Biomet deal, given that the partnership now only covers markets...
At SEB’s Nordic Seminar, Bactiguard’s CEO, Christine Lind, presented its technology and provided an update on the strategy to secure growth.
The Q2 report showed that Covid-19 is still challenging for Bactiguard, although it showed signs of stabilisation in BD licence revenues.
Bactiguard’s Q2 sales of SEK 46m were in line with our expectations, however, excluding a milestone payment from Zimmer Biomet (SEK 8.
